Oramed Pharmaceuticals Inc (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company, has screened the first patients in its global Phase three trials of its oral insulin capsule ORMD-0801 intended for the treatment of type two diabetes, it was reported on Tuesday.
The patients were screened at United States sites participating in the company's ORA-D-013-1 trial, one of two Phase three trials being conducted in accordance with United States Food and Drug Administration (FDA) approved protocols.
Both Phase 3 trials, ORA-D-013-1 and ORA-D-013-2 are intended to treat type 2 diabetes patients who have inadequate glycaemic control over a period of 6 to 12 months. The double-blinded, placebo-controlled, multi-centre randomised trials are to hire a total of 1,125 patients to evaluate the efficacy and safety of the product. Efficacy data will be revealed after all patients have completed the first six-month treatment period.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients